Then it was observed that in RA patients (Table 3): Firstly, Response rate showed a different trend but no statistical significance (P=0.083) among double csDMARDs combination (37.8%), triple csDMARDs combination (59.7%), TNFi+MTX (64.7%), and TCZ ± MTX (44.4%), respectively; Secondly, LDA rate (P=0.374) and remission rate (P=0.720) were not different among these four kinds of treatments; Thirdly, MALT1 (P=0.317), Th1 cells (P=0.292), and Th17 cells (P=0.905) were not different by these four kinds of treatments; Fourthly, Th2 cells (P=0.042) were varied by these four kinds of treatments. The gene discussed is MALT1; the disease is rheumatoid arthritis.